Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Cariprazine in Patients With Chronic Stable Schizophrenia

ClinicalTrials.gov ID: NCT00839852

Public ClinicalTrials.gov record NCT00839852. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Long-term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an outpatient study to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.

Study identification

NCT ID
NCT00839852
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Forest Laboratories
Industry
Enrollment
97 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 61 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 30, 2009
Primary completion
Aug 30, 2010
Completion
Aug 30, 2010
Last update posted
Aug 21, 2019

2009 – 2010

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
Forest Investigative Site Costa Mesa California 92626
Forest Investigative Site Long Beach California 90813
Forest Investigative Site Oceanside California 92056
Forest Investigative Site Paramount California 90723
Forest Investigative Site Riverside California 92506
Forest Investigative Site Washington D.C. District of Columbia 20016
Forest Investigative Site Bradenton Florida 34208
Forest Investigative Site Kissimmee Florida 34741
Forest Investigative Site Lake Charles Louisiana 70601
Forest Investigative Site Baltimore Maryland 21202
Forest Investigative Site Flowood Mississippi 39232
Forest Investigative Site Creve Coeur Missouri 63141
Forest Investigative Site Cincinnati Ohio 45267
Forest Investigative Site Charleston South Carolina 29405
Forest Investigative Site Memphis Tennessee 38119
Forest Investigative Site Houston Texas 77008
Forest Investigative Site Irving Texas 75062

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00839852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 21, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00839852 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →